Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group

International Journal of Colorectal Disease

Volumn 23, Issue 11, 2008, Pages 1033-1039

  Muller C I ^a   Schulmann, K ^b   Reinacher Schick, A ^b   Andre, N ^b   Arnold, D ^c   Tannapfel, A ^d   Arkenau, H ^e   Hahn, S A ^f   Schmoll, S H J ^c   Porschen, R ^g   Schmiegel, W ^b,d   Graeven, Ullrich ^h  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g KLINIKUM BREMEN OST   (Germany)

^h Krankenhaus St Franziskus   (Germany)

Author keywords

Chemotherapy; Colorectal cancer; Microsatellite instability; Prognosis

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER INCIDENCE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DNA, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 54049146248     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-008-0504-2     Document Type: Article

References (42)

1. Ferlay J, Bray F, Pisani P et al (2004) GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase no. 5, version 2.0. IARC, Lyon, France
2. Kelly HGoldberg RM (2005) Systemic therapy for metastatic colorectal cancer: Current options, current evidence. J Clin Oncol 23:4553-4560
3. Meyerhardt JAMayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476-487
4. Jiricny JNyström-Lahti M (2000) Mismatch repair defects in cancer. Curr Opin Genet Dev 10:157-161
5. Grady WM (2004) Genomic instability and colon cancer. Cancer Metastasis Rev 23:11-27
6. Lynch HT, Boland CR, Rodriguez-Bigas MA et al (2007) Who should be sent for genetic testing in hereditary colorectal cancer syndromes? J Clin Oncol 25:3534-3542
7. Thibodeau SN, French AJ, Cunningham JM et al (1998) Microsatellite instability in colorectal cancer: Different mutator phenotypes and the principial involvement of hMLH1. Cancer Res 58:1713-1718
8. Cunningham JM, Christensen ER, Tester DJ et al (1998) Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 58:3455-3460
9. Kane MF, Loda M, Gaida GM et al (1997) Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57:808-811
10. Veigl ML, Kasturi L, Olechnowicz J et al (1998) Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A 95:8698-8702
11. Herman JG, Umar A, Polyak K et al (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95:6870-6875
12. Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609-618
13. Hemminki A, Mecklin JP, Jarvinen H et al (2000) Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 119:921-928
14. Elsaleh H, Joseph D, Grieu F et al (2000) Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355:1745-1750
15. Ribic CM, Sargent DJ, Moore MJ et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257
16. Carethers JM, Smith EJ, Behling CA et al (2004) Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126:394-401
17. Jover R, Zapater P, Castells A et al (2006) Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 55:848-855
18. Benatti P, Gafa R, Barana D et al (2005) Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 11:8332-8340
19. Carethers JM, Chauhan DP, Fink D et al (1999) Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117:123-131
20. Tajima A, Hess MT, Cabrera BL et al (2004) The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: Implications for chemosensitivity and resistance. Gastroenterology 127:1678-1684
21. Arnold CN, Goel A, Boland CR (2003) Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 106:66-73
22. Brueckl WM, Moesch C, Brabletz T et al (2003) Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Anticancer Res 23:1773-1777
23. Liang JT, Huang KC, Lai HS et al (2002) High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer 101:519-525
24. Chen WS, Chen JY, Liu JM et al (1997) Microsatellite instability in sporadic-colon-cancer patients with and without liver metastases. Int J Cancer 74:470-474
25. Kochhar R, Halling KC, McDonnell S et al (1997) Allelic imbalance and microsatellite instability in resected Duke's D colorectal cancer. Diagn Mol Pathol 6:78-84
26. des Guetz G, Mariani P, Cucherousset J et al (2007) Microsatellite instability and sensitivity to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res 27:2715-2719
27. Fink D, Nebel S, Aebi S et al (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881-4886
28. Fink D, Zheng H, Nebel S et al (1997) In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57:1841-1845
29. Porschen R, Arkenau HT, Kubicka S et al (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO Colorectal Study Group. J Clin Oncol 25:4217-4223
30. Diaz-Rubio E, Tabernero J, Gomez-Espana A et al (2007) Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 25:4224-4230
31. Cassidy J, Clarke S, Diaz-Rubio E et al (2007 ASCO Annual Meeting Proceedings) XELOX compared to FOLFOX4: Survival and response from XELOX-I/NO16966, a randomized phase III trial of first-line treatment for metastatic colorectal cancer (MCRC). J Clin Oncol 25(18s) (suppl; abstr 4030)
32. Kunstmann E, Vieland J, Brasch FE et al (2004) HNPCC: Six new pathogenic mutations. BMC Med Genet 5:16
33. Dietmaier W, Wallinger S, Bocker T et al (1997) Diagnostic microsatellite instability: Definition and correlation with mismatch repair protein expression. Cancer Res 57:4749-4756
34. Lindor NM, Burgart LJ, Leontovich O et al (2002) Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 20:1043-1048
35. Ruszkiewicz A, Bennett G, Moore J et al (2002) Correlation of mismatch repair genes immunohistochemistry and microsatellite instability status in HNPCC-associated tumours. Pathology 34:541-547
36. Boland C, Thibodeau S, Hamilton S et al (1998) A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248-5257
37. Zhou XP, Hoang JM, Li YJ et al (1998) Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer 21:101-107
38. Kaplan EMeier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 158:23-39
39. Gonzalez-Garcia I, Moreno V, Navarro M et al (2000) Standardized approach for microsatellite instability detection in colorectal carcinomas. J Natl Cancer Inst 92:544-549
40. Lothe RA, Peltomaki P, Meling GI et al (1993) Genomic instability in colorectal cancer: Relationship to clinicopathological variables and family history. Cancer Res 53:5849-5852
41. Jernvall P, Makinen MJ, Karttunen TJ et al (1999) Microsatellite instability: Impact on cancer progression in proximal and distal colorectal cancers. Eur J Cancer 35:197-201
42. Evertson S, Wallin A, Arbman G et al (2003) Microsatellite instability and MBD4 mutation in unselected colorectal cancer. Anticancer Res 23:3569-3574